Researchers at Mount Sinai have developed a novel approach to cancer immunotherapy, injecting immune stimulants directly into a tumor to teach the immune system to destroy it and other tumor cells throughout the body.
The “in situ vaccination” worked so well in patients with advanced-stage lymphoma that it is also undergoing trials in breast and head and neck cancer patients, according to a study published in Nature Medicine in April.
The treatment consists of administering a series of immune stimulants directly into one tumor site. The first stimulant recruits important immune cells called dendritic cells that act like generals of the immune army. The second stimulant activatesthe dendritic cells, which then instruct T cells, the immune system’s soldiers, to kill cancer cells and spare non-cancer cells. This immune army learns to recognize features of the tumor cells so it can seek them out and destroy them throughout the body, essentially turning the tumor into a cancer vaccine factory.
“The in situ vaccine approach has broad implications for multiple types of cancer,” said lead author Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. “This method could also increase the success of other immunotherapies such as checkpoint blockade.”
After testing the lymphoma vaccine in the lab, it was tested in 11 patients in a clinical trial. Some patients had full remission from months to years. In lab tests in mice, the vaccine drastically increased the success of checkpoint blockade immunotherapy, the type of immunotherapy responsible for the complete remission of former President Jimmy Carter’s cancer and the focus of the 2018 Nobel Prize in Medicine.
A clinical trial for lymphoma, breast, and head and neck cancer patients opened in March to test the vaccine with checkpoint blockade drugs. Because the combined immune therapy was at least three times more powerful than either checkpoint blockade or the vaccine by themselves, researchers are extremely optimistic about how effective this may be in patients in this new trial. The in situ vaccine is also being tested in the lab in liver and ovarian cancer.
The Latest on: Cancer immunotherapy
via Google News
The Latest on: Cancer immunotherapy
- MSD Philippines' cancer awareness campaign wins Anvil Awardon May 28, 2020 at 10:58 pm
Merck Sharp & Dohme (MSD) Philippines' multi-stakeholder cancer advocacy campaign ‘Hope From Within’ with 2 Silver Anvil Awards.
- Bacterial colonies of tumors could guide cancer careon May 28, 2020 at 7:19 pm
The human body is teeming with bacteria, and a new study finds the same is true of many cancers -- raising questions about what role microbes might play in the diseases.
- Immunotherapy Potentially Curative in Rare Placenta Canceron May 28, 2020 at 2:07 pm
Eight of 15 women (53%) with the rare gynecologic cancer had normalization of their human chorionic gonadotropin (hCG) levels following treatment with the PD-L1-directed immune checkpoint inhibitor, ...
- Immunotherapy improves survival in patients with advanced bladder canceron May 28, 2020 at 2:03 pm
An immunotherapy drug called 'avelumab' has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial ...
- Novel biomarkers predict benefit with immunotherapy in metastatic breast canceron May 28, 2020 at 1:56 pm
Two novel biomarkers have been found to correlate with improved outcomes with immunotherapy in metastatic breast cancer and may help to identify the patients most likely to benefit from this treatment ...
- Tumors Have Their Own Bacterial Colonies That Could Guide Cancer Careon May 28, 2020 at 12:09 pm
The human body is teeming with bacteria, and a new study finds the same is true of many cancers -- raising questions about what role microbes might play in the diseases. Researchers have already known ...
- New drug combinations could help overcome genetic immunotherapy resistanceon May 28, 2020 at 10:55 am
A new study from researchers at the UCLA Jonsson Comprehensive Cancer Center helps explain how disruptions in genes can lead to the resistance to one of the leading immunotherapies, PD-1 blockade, and ...
- Researchers develop promising immunotherapy treatment for glioblastomaon May 27, 2020 at 11:28 am
Researchers of McMaster University and the University of Toronto have developed a promising immunotherapy treatment for a deadly form of adult brain cancer called glioblastoma.
- Immunotherapy for triple-negative breast cancer approved for NHS in Englandon May 27, 2020 at 8:31 am
The National Institute for Health and Care Excellence (NICE) has approved a new immunotherapy treatment option for some adults with triple negative breast cancer in England.
- New cancer immunotherapy targeting myeloid cells slows tumor growthon May 27, 2020 at 8:28 am
Checkpoint inhibitors, a type of immunotherapy, that target myeloid immune cells and slow tumor growth were discovered by a team from the Perelman School of Medicine at the University of Pennsylvania ...
via Bing News